跳至主要内容
临床试验/NCT05143489
NCT05143489终止4 期

The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast: A Double-blinded, Randomized-control Trial

Antonios Likourezos1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2022年1月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
3
试验地点
1
主要终点
Pain Score at 15 Minutes Post Medication Administration

研究概览

简要总结

Intravenous contrast media is commonly used for CT scans for improved image clarity in pediatric emergency medicine. Children who feel discomfort during the administration of IV contrast media may not remain still during the CT scan, which affects the overall study quality and reliability. Therefore, many young patients often undergo procedural sedation in anticipation of movement artifact degrading the diagnostic accuracy. Procedural sedation, while a common procedure in the pediatric emergency department, does have significant complications, and it increases the risk of adverse events for the patient. The risk of airway compromise associated with procedural sedation is particularly concerning in children requiring IV contrast for imaging of an upper airway pathology such as retropharyngeal abscess, as the disease itself narrows the airway. This presents the physician with a dilemma of assessing the extent of the disease without the additional risk of airway compromise by using procedural sedation.Previous research has looked at premedication with steroids prior to IV-contrast media administration to avert an allergic response. However, there has been no investigation of premedication to abate the immediate adverse effects of discomfort associated with IV contrast injection. The safety of IV lidocaine in pediatric patients has been documented in studies of its use for post-operative pain, using doses from 1.0 to 1.5 mg/kg with no known adverse side effects. CT scans with IV contrast are performed on a near-daily basis in the Maimonides pediatric emergency department, usually for the assessment of acute appendicitis. The standard of care in children and adults receiving IV contrast does not include pre-medication to prevent IV contrast-associated discomfort. This double-blinded prospective study aims to determine whether pre-treatment with lidocaine can mitigate the immediate discomfort of IV contrast in verbal children and adolescents who can comply with a pre and post IV contrast pain assessment.

详细描述

STUDY DESIGN Subjects: Patients aged from 7 to 17 years-old who present to the Maimonides Medical Center's Emergency Department that require a CT scan with IV contrast. Research team members will be notified when the patient requires CT scan with IV contrast and meets the eligibility criteria. Potential subjects will be recruited in the Emergency Department

Eligibility Criteria: Inclusion criteria: Patients with age of 7 to 17 years-old who require a CT scan with IV contrast. Exclusion criteria: Patients with history of seizures, cardiovascular disease, presenting as a trauma, a history of anaphylaxis to lidocaine, or children/adolescents with underlying neurodevelopmental conditions which would interfere with their ability to respond to pre and post IV contrast pain assessments.

Design: This is a prospective, double-blinded randomized control study that will be comparing intravenous lidocaine to a placebo. Patients will be randomized with block randomization. The randomization list will be generated EM Research Manager and given to the EM pharmacist a priori of commencement of the study. The EM Research Manager and EM Pharmacist are not blinded to the study. Once a potential subject has been identified, a member of the research team will obtain consent from the parent or guardian of the subject. The research team member involved with consent and data collection, provider, and subject will all be blinded to which treatment arm they are assigned.

The research team members will monitor each patient and in conjunction with the pharmacy will deliver the assigned treatment to the subject's nurse to administer 10 min prior to the CT scan. If selected for the treatment group, the patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.15 A patient selected to the control group will an equal volume of normal saline infused. A research team member will be present during the administration of assigned treatment until the completion of the CT scan. The patient will be placed on a cardiopulmonary monitor for the duration of this period. Advanced airway equipment, IV midazolam, and IV intralipids will also be available at bedside during infusion and until completion of CT scan to treat any potential adverse effect associated with lidocaine.

Nominal variables to be collected include gender, chief complaint, pain score at triage, use of pain medication at triage and during the ED course, diagnosis, type of CT scan performed, pre and post-intervention pain score, post-intervention pruritus score, post-intervention burning pain score. The only continuous variable being collected includes age (in years-old).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
7 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patients with age of 7 to 17 years-old who require a CT scan with IV contrast
  • Require CT scan with IV contrast

排除标准

  • History of seizures
  • Cardiovascular disease
  • Presenting as a trauma
  • a history of anaphylaxis to lidocaine
  • children/adolescents with underlying neurodevelopmental conditions which would interfere with their ability to respond to pre and post IV contrast pain assessments.

研究组 & 干预措施

Preservative Free Lidocaine Group

Active Comparator

The patient will receive a 1mg/kg IV dose of preservative free lidocaine with a max dose of 40mg

干预措施: Preservative Free Lidocaine (Drug)

Placebo Group

Active Comparator

The patient will receive IV normal saline of 1mg/kg with a max of 40mg

干预措施: Saline (Drug)

结局指标

主要结局

Pain Score at 15 Minutes Post Medication Administration

时间窗: 15 minutes

We will use a combination of the Baker-Wong FACES pain scale and 1 to 10 numerical scale for pain as well as a 5-point Likert scale for discomfort. Both scales range from no pain to very severe pain with 5 being moderate pain.

Pain Score at 30 Minutes Post Medication Administration

时间窗: 30 minutes

We will use a combination of the Baker-Wong FACES pain scale and 1 to 10 numerical scale for pain as well as a 5-point Likert scale for discomfort. Both scales range from no pain to very severe pain with 5 being moderate pain.

次要结局

  • Pain Score at 120 Minutes Post Medication Administration(120 minutes)
  • Pain Score at 60 Minutes Post Medication Administration(60 minutes)
  • Pain Score at 90 Minutes Post Medication Administration(90 minutes)

研究者

发起方
Antonios Likourezos
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Antonios Likourezos

Research Administration Director

Maimonides Medical Center

研究点 (1)

Loading locations...

相似试验

The Effect of Pretreatment With Intravenous... | 临床试验